Advaxis cervical-cancer drug gets orphan designation

Advaxis' (ADXS) ADXS-HPV immunotherapy treatment for Stage II-IV invasive cervical cancer has received Orphan Drug Designation from the FDA.

ADXS-HPV has already generated encouraging Phase 2 data.

Shares are +8.5%. (PR)

Comments (1)
  • pagreen1966
    , contributor
    Comments (661) | Send Message
    One of the only good things about the recent biotech sell off was that the baby was thrown out with the bath water and excellent companies like (ADXS) were also hit hard giving us an excellent opportunity to buy the stock at bargain prices.


    Some very savvy analysts give this company a $10 price target over the next 12 months and that was before todays announcement!
    1 May 2014, 09:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs